The question
Must every cancer pass through immune removal, a standoff and escape?
This is the specific idea being tested.
The Hypothesis Critic · A guide for everyone
Immunoediting (elim–equil–escape)
Must every cancer pass through immune removal, a standoff and escape?
What you need to knowThe immune system can shape cancers, but the same three-stage sequence is not established for every tumour.Relative explanatory fit: Alternative ranked ahead
Why the alternative fits better: Immune recognition and a tumour's origin change how it develops.
Review summary
Claim assessed: The immune system actively sculpts tumors, driving all developing tumors through an obligate sequence of elimination, equilibrium and escape while selecting immune-resistant variants.
Finding: SC6 gates the registered universal scope and remains Β. Human phase histories are chiefly inferred from sampled lesions/genomes without an all-etiology causal inception dataset. This does not cap scoped immune elimination or presentation escape, which reach Ζ through matching genetic and functional contrasts. Low-antigen KPC, innate-only editing and early evasion delimit the universal inference.
Key points
- SC1: Adaptive immunity eliminates nascent transformed cells in vivo. — HSEF Ζ, Moderate confidence.
- SC2: Adaptive immunity maintains occult transformed cells in equilibrium. — HSEF Δ, Moderate confidence.
- SC3: Untreated tumor escape occurs through point-mutational neoantigen depletion under selection. — HSEF Ε, Moderate confidence.
- SC4: Immune selection causes loss of antigen-presentation capacity including HLA LOH. — HSEF Ζ, Moderate confidence.
- SC5: Reversible epigenetic neoantigen silencing mediates immune escape. — HSEF Γ, Moderate confidence.
- SC6: Every developing human tumor follows the obligate three-phase sequence. — HSEF Β, Moderate confidence.
Verdict and review details
- Evidence grade
- HSEF Β — Associational
- Confidence
- Moderate
- Framework
- HSEF v5.3
- Review date
- Literature cutoff
- Published
- Review attribution (recorded)
- Codex
Evidence scope: 63 primary reports; literature cutoff 2026-10-08; source examination UTC date 2026-10-09; bounded critical review, not exhaustive systematic review.
The grade applies to the stated claim. Model rankings and individual subclaim grades remain separate from the overall causal-evidence grade.
Full scientific assessment and references · Scorecard (JSON) · Review source (Markdown)
The result at a glance
The immune system can shape cancers, but the same three-stage sequence is not established for every tumour.
Read the labels in this illustration
THE MAIN FINDING The immune system can shape cancers, but the same three-stage sequence is not established for every tumour. The idea Must every cancer pass through immune removal, a standoff and escape? Elimination Equilibrium Escape Proposed universal sequence; its occurrence and order must be tested. What fits better Immune effects differ between cancers Best fit in this review Tumour origin Recognisable antigens Immune context Possible removal Persistent restraint Outgrowth with weak recognition or evasion Possible routes; no universal order established. What remains uncertain Which cancers undergo sustained immune restraint? Which routes operate early in untreated human tumours? When does altered immune recognition change tumour outgrowth? Evidence comes from cells, animals and people; scope differs between settings. Immune recognition and a tumour's origin change how it develops. Conceptual illustration
Best fit in this review
Immune effects differ between cancers
Immune recognition and a tumour's origin change how it develops.
Evidence for the stated claim
Association only
A higher rank means a better fit to the evidence in this comparison. It does not prove every part of the leading explanation.
Which explanation fits?
Another explanation fits better.
A separate question from the causal evidence grade
How does this explanation compare with alternatives?
Alternative ranked aheadThe reviewed hypothesis ranks 5 among 5 models compared; 1 alternative model(s) hold first rank for this stated claim.
Claim under review: rank 5 among 5 compared models.
Leading explanation: Etiology-stratified immune editing.
Position in this comparison: Last recorded rank.
The causal grade asks how well the stated causal claim is established. This comparison asks which of the assessed explanations fits the reviewed findings better. A leading explanation can remain unproven. Models can overlap or include the tested mechanism; an alternative ahead does not make that mechanism irrelevant. These ordinal ranks apply within this review; they do not measure the size of a difference or rank scientific strength across topics.
Read the labels in this illustration
TWO EXPLANATIONS, COMPARED A · The idea under review Must every cancer pass through immune removal, a standoff and escape? Proposed universal sequence Elimination Equilibrium Escape Dashed arrows show the universal sequence being tested. Immune selection is causal in defined cancers; a compulsory three-stage sequence across human cancers remains unestablished. B · Leading explanation Immune effects differ between cancers Best fit in this review Tumour origin Recognisable antigens Immune context Possible removal Persistent restraint Outgrowth with weak recognition or evasion Possible routes depend on tumour origin, immune recognition and immune context. A better fit is not proof of every part of the explanation. Immune selection can occur without every tumour following the same sequence. Conceptual illustration
Idea being tested · rank 5
Must every cancer pass through immune removal, a standoff and escape?
Association only for the stated claim.
Best fit in this review · rank 1
Immune effects differ between cancers
Immune recognition and a tumour's origin change how it develops.
These explanations can overlap. Ranking their fit to the evidence is separate from deciding how firmly a cause has been established.
See all the explanations compared
Rank 1: Etiology-stratified immune editing — Baseline antigenicity, lineage and immunity determine editing routes.
Rank 2: Antigen-presentation attrition — Mutations can persist while HLA/B2M presentation or recognition fails.
Rank 3: Immunological ignorance — Expressed antigens need not recruit effective specific recognition.
Rank 4: Innate/myeloid pre-emption — Lineage and early suppressive niches permit outgrowth before effective adaptive engagement.
Rank 5: Universal obligatory three phases — All developing human tumors require sequential adaptive elimination, equilibrium and escape.
What this means
?
Association only
The immune system can shape cancers, but the same three-stage sequence is not established for every tumour.
Evidence rating: Β · Moderate confidence. How the evidence was assessed.
The important distinction
Immune recognition and a tumour's origin change how it develops.
Health and treatment
SC6 gates the registered universal scope and remains Β. Human phase histories are chiefly inferred from sampled lesions/genomes without an all-etiology causal inception dataset. This does not cap scoped immune elimination or presentation escape, which reach Ζ through matching genetic and functional contrasts. Low-antigen KPC, innate-only editing and early evasion delimit the universal inference.
From an idea to an explanation
Seeing two things together does not prove one causes the other.
What is observed?
Look for the proposed factor and the outcome, in the people or systems covered by the claim.
What else explains it?
Immune effects differ between cancers. Immune recognition and a tumour's origin change how it develops.
What test tells them apart?
Track developing tumours and immune recognition to test whether the proposed stages occur.
What to test next
What evidence would make the answer clearer?
Read the labels in this illustration
WHAT WOULD MAKE THE ANSWER CLEARER A research question Track developing tumours and immune recognition to test whether the proposed stages occur. Test immune recognition in defined animal models Proposed test animals Immune recognition intact Selectively interrupted Restored after interruption Matched handling control Use matched controls; verify interruption and restoration. Measure the relevant outcome Proposed test animals Tumour clearance Are tracked tumour clones eliminated? Persistent viable tumour cells Is there evidence of immune restraint, and for how long? Tumour outgrowth How do antigen presentation and recognition change? people · separate observational follow-up Track developing lesions and immune recognition Human observations alone do not prove a causal three-stage history. Trace the same outcomes in each model arm; compare with separate human follow-up. Check the result independently Proposed test First team measures Second team repeats Use the same prespecified endpoints and include another tumour context. This storyboard shows the logic of a test. It does not show a result. The question is whether the stages occur, in what order, and under which conditions. Conceptual illustration
A useful next question
Track developing tumours and immune recognition to test whether the proposed stages occur.
Change the proposed cause
Check that the intended change really happened.
Measure the relevant outcome
Allow for other factors and compare with suitable controls.
Check whether it holds up
Look for independent confirmation and the limits of the effect.
These are questions for research, not a claim that the proposed studies have already succeeded.
Read the scientific study designs
Proposed tests: 1 test design(s) are registered in the scorecard.
In plain terms, researchers would change the proposed cause, check that it changed as intended, then measure a meaningful outcome while controlling plausible alternatives. The result should be able to support or count against the claim—not only show that a pathway exists.
Experiment 1: Registered boundary experiment
Study design: Prospectively barcode autochthonous clones across predefined high/low-antigen etiologies; serially trace immune contact, viable occult persistence and outgrowth with delayed antigen-specific interruption and physiological restoration; pair with untreated human surveillance.
What would be measured: Clone survival, occult proliferation balance, antigen/presenter substrate, autologous recognition and tumor outcomes
Important controls: Antigen-negative lineages, tolerant/depleted/intact hosts, restoration, CIN-matched HLA passengers, mutation-signature nulls and blinded phase labels
Result that would support the claim: Every predefined developing clone traverses causally verified sequential phases with matching interruption/restoration effects
Result that would count against it: Tracked clones bypass the required adaptive phase or inherit early escape without preceding causal equilibrium
Explore the evidence
Read the complete scientific review.
Follow the studies, detailed comparisons and evidence ratings behind this guide.
Open the scientific review →